Edesa Biotech Book Value | EDSA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Edesa Biotech

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
13.5 M	1.98 M	7.05 M	9.39 M	13.1 M	6.63 M	5.26 M	11.3 M	7.4 M	12.3 M	8.01 M	7.7 M	-3.14 M	852 K	4.59 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
13.5 M	-3.14 M	7.06 M

Quarterly Book Value Edesa Biotech

2026-Q3	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
13.5 M	12.4 M	14.7 M	-	-	-	-	-	-	2.87 M	-	5.84 M	7.05 M	7.85 M	9 M	10.3 M	9.39 M	11.8 M	17 M	10.5 M	13.1 M	15.8 M	13.1 M	9.26 M	9.11 M	9.11 M	9.11 M	4.23 M	5.26 M	5.26 M	5.26 M	3.4 M	11.8 M	3.4 M	10.5 M	6.59 M	7.72 M	7.72 M	7.72 M	11.5 M	12.9 M	12.9 M	12.9 M	10.4 M	8.01 M	8.61 M	7.48 M	9.24 M	10.5 M	10.5 M	10.5 M	-	5.36 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
17 M	2.87 M	9.34 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	29.8 B	-	-	-	Russia
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	357 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	-13.3 M	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	1.63 B	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	270 M	$ 101.8	0.08 %	$ 6.62 B	USA
Rezolute RZLT	162 M	$ 4.4	0.88 %	$ 334 M	USA
Sana Biotechnology SANA	161 M	$ 3.45	0.77 %	$ 874 M	USA
Seer SEER	259 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	20.9 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	199 M	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	64.6 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	5.29 M	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	42.5 M	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	1.14 B	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	352 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	-132 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	82.4 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	1.06 B	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	203 M	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	29.7 M	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	6.94 T	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	2.59 B	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	97.1 M	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	7.91 B	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	648 M	$ 55.74	0.58 %	$ 8.04 B	USA
Trevi Therapeutics TRVI	183 M	$ 16.82	1.17 %	$ 2.27 B	USA
Taysha Gene Therapies TSHA	247 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	22.8 M	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	-105 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	7.1 B	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	59 M	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	245 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	183 M	-	-	$ 98.4 M	USA
NextCure NXTC	34.9 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	24.7 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	722 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	33 M	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	18.7 B	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	57.2 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	64.4 M	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	196 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	526 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	245 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	7.4 M	$ 4.28	0.86 %	$ 7.28 M	USA
XBiotech XBIT	140 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	3.93 M	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	582 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	13.7 M	$ 8.48	0.12 %	$ 1.36 B	USA